A Senomorphic‐Conjugated Scaffold for Application of Senescent Cells in Regenerative Medicine

Procuring a sufficient amount of cells is essential for cell-based regenerative therapy. However, the application senescent replicated using cell culture limited because have lost their ability or produce deleterious senescence-associated secretory phenotypes (SASPs). In this study, senomorphic (epigallocatechin gallate [EGCG]), which could modulate SASP secretion from cells, nonsenescent and dedifferentiated fat rats (rDFAT cells), congenital cleft-jaw defects in rats, authors show that (EGCG)-conjugated cellular scaffold restores bone multipotent progenitor even vivo. osteogenic process, EGCG-conjugated attenuates production representative SASPs (i.e., interleukin [IL]-6 tumor necrosis factor-α) reactive oxygen species vivo vitro. polymerase chain reaction arrays vitro, suppresses expression genes associated with factors formation (e.g., Csf2, IL-1a, others) rDFAT elevates potential osteogenesis- remodeling- related gene Cxcl13 Spp1). These results provide insights to expand senomorphics stem/multipotent medicine.